1. Medtech Insight
  2. >>Business

Pacts In Medtech: BI, Inflammasome Work On Retinal Disease; Takeda And Prometheus Take On IBD

 
• By Reed Miller

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.

Pacts In Medtech

Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candidates for retinal diseases.

BI will provide up to $160m in up-front, R&D, and milestone payments, plus tiered royalties and additional commercialization milestones. The deal combines compounds from the Big Pharma's retinal disease pipeline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business